

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1611544> since 2017-06-08T00:39:16Z

Published version:

DOI:10.1111/liv.13193

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



Impact of Viral Eradication with Sofosbuvir-based Therapy on the Outcome of Post-Transplant Hepatitis C with Severe Fibrosis

Journal:	<i>Liver International</i>
Manuscript ID	LIVint-16-00427.R2
Wiley - Manuscript type:	Original Articles
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Martini, Silvia; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Sacco, Marco; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Strona, Silvia; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Arese, Daniele; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Tandoi, Francesco; AOU Città della Salute e della Scienza di Torino, Liver Transplantation Center, General Surgery Unit 2U Dell Olio, Dominic; AOU Città della Salute e della Scienza di Torino, Regional Transplantation Center, Piedmont Stradella, Davide; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Cocchis, Donatella; AOU Città della Salute e della Scienza di Torino, Liver Transplantation Center, General Surgery Unit 2U Mirabella, Stefano; AOU Città della Salute e della Scienza di Torino, Liver Transplantation Center, General Surgery Unit 2U Rizza, Giorgia; AOU Città della Salute e della Scienza di Torino, Liver Transplantation Center, General Surgery Unit 2U Magistrone, Paola; AOU Città della Salute e della Scienza di Torino, Regional Transplantation Center, Piedmont Moschini, Pamela; AOU Città della Salute e della Scienza di Torino, Regional Transplantation Center, Piedmont Ottobrelli, Antonio; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Amoroso, Antonio; AOU Città della Salute e della Scienza di Torino, Regional Transplantation Center, Piedmont Rizzetto, Mario; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Salizzoni, Mauro; AOU Città della Salute e della Scienza di Torino, Liver Transplantation Center, General Surgery Unit 2U Saracco, Giorgio; AOU Città della Salute e della Scienza di Torino, Gastrohepatology Unit Romagnoli, Renato; AOU Città della Salute e della Scienza di Torino, Liver Transplantation Center, General Surgery Unit 2U</p>
Keywords:	Liver transplantation, HCV recurrence, Direct-acting antivirals, Non-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	invasive fibrosis tests, Survival

SCHOLARONE™
Manuscripts

For Peer Review

1
2
3 **Impact of Viral Eradication with Sofosbuvir-based Therapy on the Outcome**
4
5 **of Post-Transplant Hepatitis C with Severe Fibrosis**
6
7

8
9 Silvia Martini,¹ Marco Sacco,¹ Silvia Strona,¹ Daniele Arese,¹ Francesco Tandoi,²
10
11 Dominic Dell Olio,³ Davide Stradella,¹ Donatella Cocchis,² Stefano Mirabella,²
12
13 Giorgia Rizza,² Paola Magistri,³ Pamela Moschini,³ Antonio Ottobrelli,¹
14
15 Antonio Amoroso,³ Mario Rizzetto,¹ Mauro Salizzoni,²
16
17 Giorgio M. Saracco,¹ Renato Romagnoli²
18
19

20
21
22
23 ¹Gastrohepatology Unit

24
25 ²Liver Transplantation Center, General Surgery Unit 2U

26
27 ³Regional Transplantation Center, Piedmont

28
29 AOU Città della Salute e della Scienza di Torino, University of Turin, Italy
30
31
32
33
34
35

36 **Correspondence information**

37
38 Silvia Martini, MD

39
40 Gastrohepatology Unit, AOU Città della Salute e della Scienza di Torino

41
42 Corso Bramante, 88 - 10126 Turin - Italy

43
44 Phone: +39 011 6335928; fax: +39 011 6334014

45
46 E-mail address: sivima21@hotmail.com
47
48
49

50
51 Electronic word count for main body of the manuscript: 4337.

52
53 Number of figures: 2. Number of tables: 3.
54
55
56
57
58
59
60

List of abbreviations in the order of appearance:

HCV, hepatitis C virus; LT, liver transplantation; Peg-IFN, pegylated-interferon; SVR, sustained virological response; SVR12, sustained virological response at week 12 after the end of treatment; DAAs, direct-acting antiviral agents; LS, liver stiffness; kPa, kilopascal; EOT, end of therapy; *IL28B*, *Interleukin 28B*; HLA, human leukocyte antigen; AE, adverse event; AST, aspartate aminotransferase; APRI, AST to platelet ratio index; ALT, alanine aminotransferase; SVR24, sustained virological response at week 24 after the end of treatment; ROC, receiver operating characteristic; MELD, Model for End-stage Liver Disease; F, fibrosis; ITT, intention to treat.

Conflict of interest

MR is an Advisory Board member for AbbVie, BMS, Gilead, Janssen, MSD.

GMS is an Advisory Board member for AbbVie, Gilead and MSD.

SM is a Regional Advisory Board member for Gilead.

The other Authors who have taken part in this study declared no conflict of interest.

Financial support

This work was unsupported.

ABSTRACT

Background & Aims. Several studies have shown that new direct-acting-antivirals (DAAs) maintain their efficacy in liver transplant (LT) recipients with severe HCV recurrence. We determined the clinical impact of Sofosbuvir/Ribavirin in LT through the changes in liver function and fibrosis state at 24 and 48 weeks after treatment.

Methods. Between 06/2014 and 07/2015, 126 patients (30 F3, 96 F4 Metavir stage) were enrolled to receive sofosbuvir+ribavirin (24 weeks, 118 patients) or sofosbuvir+simeprevir+ribavirin (12 weeks, 8 patients); treatment was initiated at a median time of 4.3 years from LT. Median follow-up after therapy completion was 461 days.

Results. All 30 F3 patients achieved a sustained virological response at week 24 after treatment (SVR24), and showed a distinct amelioration of the AST-to-platelet-ratio-index (APRI), FIB-4 and liver stiffness at elastography by week 24 post-therapy, which were maintained at week 48.

Of the 96 F4 cirrhotic patients, 72 (75%) achieved SVR24 accompanied by significant improvement of liver function, which was maintained at week 48 (Child B-C 22% baseline, 11% week 24, 7% week 48); APRI, FIB-4, liver stiffness further improved significantly between week 24 and 48 of follow-up. Among the 77 responders (27 F3, 50 F4) who underwent elastography at baseline and at the end of follow-up, 39 (50.6%; 18 F3, 21 F4) exhibited a regression in fibrosis stage. *Conclusion.* At about one-year from the completion of successful sofosbuvir-based therapy, patients with post-LT HCV and severe fibrosis experienced a long-term liver function improvement accompanied by a regression of fibrosis stage in half of them.

Keywords

Liver transplantation; HCV recurrence; direct-acting antivirals; non-invasive fibrosis tests; survival.

Key point box

- 126 patients with post liver transplant HCV and severe fibrosis (30 F3 and 96 F4 Metavir) received a sofosbuvir-based antiviral therapy. The median follow-up after therapy was 461 days.
- All the 30 F3 patients and 72 of the 96 cirrhotics (75%) achieved a sustained virological response at week 24 after treatment.
- HCV-eradicated patients showed a distinct amelioration in AST-to-platelet-ratio-index, FIB-4 and liver stiffness at week 24 after therapy, which persisted in F3 patients and further improved in F4 ones at week 48.
- In transient elastography, the fibrosis stage regressed in half of the HCV-eradicated patients at week 48 after therapy.

Peer Review

INTRODUCTION

Hepatitis C virus (HCV) is the leading cause of cirrhosis and hepatocellular carcinoma and the most common indication for liver transplantation (LT) in Europe and United States [1].

Infection recurs almost universally in patients who have detectable serum HCV RNA at LT and it is the main cause of graft failure and patient death [2]. Successful HCV eradication is associated with reduced disease progression, and improved liver allograft and recipient survival [3].

Until few years ago, pegylated-interferon (Peg-IFN) with ribavirin was the only treatment for HCV recurrence post-LT; however its use was limited by poor efficacy and beset with significant adverse events [4]. The addition of first generation protease inhibitors, boceprevir and telaprevir, doubled the rates of sustained virological response (SVR) at 12 weeks (SVR12) in HCV genotype 1, but was aggravated by unacceptable toxicity and drug-drug interactions [5]. A major breakthrough has been the advent of second generation direct-acting antiviral agents (DAAs), which interact with different HCV functions and have markedly improved antiviral efficacy and tolerability [6], leading to HCV eradication also in patients with severe recurrent hepatitis C after LT.

The therapeutic potential of the prototype sofosbuvir was quickly perceived; the combinations of sofosbuvir with ribavirin \pm Peg-IFN and of sofosbuvir with simeprevir \pm ribavirin were reported in early international studies to achieve 59% to 88% SVR12 rates [7, 8]. A sofosbuvir compassionate use program was activated in Italy between June 2014 and December 2014; simeprevir became available later, in February 2015.

The primary target of early studies was the virologic efficacy and the tolerability of DAAs in order to meet the urgent demand from transplant patients. In this single-center study, we report the clinical outcome of therapy in a large series of patients with severe fibrosis due to hepatitis C recurrence; the majority were treated with sofosbuvir plus ribavirin, a minority with sofosbuvir plus simeprevir plus ribavirin. We focused on the changes in liver function

1
2
3 parameters and in non-invasive tests of fibrosis up to 48 weeks after the end of successful
4
5 treatment.
6
7

8 9 **PATIENTS AND METHODS**

10 **Study population**

11
12 Out of 273 surviving HCV recipients with persistent viremia following LT performed in Turin
13
14 (Italy) since January 2000, between June 2014 and May 2015 we enrolled 126 patients
15
16 with recurrent hepatitis C who exhibited a Metavir staging score ≥ 3 , and a creatinine
17
18 clearance ≥ 30 mL/min. The severity of fibrosis was determined within 6 months from
19
20 treatment by liver biopsy or by transient elastography [liver stiffness (LS) cut-off values of
21
22 9.5 kilopascal (kPa) and 12.5 kPa corresponding, respectively, to Metavir F3 and F4
23
24 fibrosis stages] [9]. Only transient elastography measurements with a success rate of at
25
26 least 60% were considered valid.
27
28
29

30
31 From June 2014 to December 2014 patients were treated in the context of the sofosbuvir
32
33 national compassionate use program; each treatment was approved by the local ethic
34
35 committee (Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di
36
37 Torino—A.O. Ordine Mauriziano—A.S.L. TO1) and the patients provided written informed
38
39 consent. By the Italian legislation, Regional Transplantation Centers are the lawful
40
41 custodians of the recipient/donor biomedical data for clinical and for research purposes. All
42
43 study procedures were compliant with the ethical standards of the 2000 Declaration of
44
45 Helsinki as well as the Declaration of Istanbul 2008.
46
47
48

49 The demographic and baseline characteristics of the study population and their donors are
50
51 shown in Table 1.
52
53
54
55
56
57
58
59
60

Study protocol

The treatment regimens consisted of sofosbuvir 400 mg once daily and ribavirin twice daily (at a dose of 1000 mg daily with body weight <75 kg, or 1200 mg daily with body weight ≥75 kg, adjusted according to haemoglobin level and renal function) for 24 weeks, or sofosbuvir 400 mg once daily, ribavirin twice daily (weight-based) and simeprevir 150 mg once daily for 12 weeks. Epoetin-alfa at 20,000-40,000 units/week was administered subcutaneously to patients with haemoglobin levels <10 g/dL.

Patients underwent clinical and laboratory assessment [HCV RNA by polymerase chain reaction technique with AmpliPrep[®]/COBAS TaqMan[®] HCV version 2 (Roche Molecular Systems, Inc., Branchburg, NJ, US), complete blood cell count, liver and kidney function tests, serum electrolytes, serum levels of immunosuppressive drugs] at baseline, weekly for the first month, then monthly while on treatment and at 1, 3, 6 and 12 months after the end of therapy (EOT). No viral resistance monitoring was performed.

At baseline, all patients were tested for HCV genotype (reverse hybridization line probe assay, INNO-LIPA, Innogenetics, Ghent, Belgium), *Interleukin 28B (IL28B)* rs12979860 C/T and rs8099917 T/G polymorphisms (Custom TaqMan[®] Allelic Discrimination Kit, Life Technologies Applied Biosystems[®], Thermo Fisher Scientific, Waltham, MA, US) and serum 25-OH vitamin D level (fully automated chemiluminescence immunoassay, ADVIA Centaur[®] Vitamin D Total assay, Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA). Human leukocyte antigen (HLA) DRB1 typing was collected as well (performed before transplant, by serology methods until 2006 and then by molecular low-resolution), paying particular attention to HLA-DRB1*11 phenotype [10]. Adverse events (AE), drug dose modifications, use of growth factors, blood transfusions, and need for hospitalisation during treatment were recorded.

To assess the changes in fibrosis evolution in virological responders, transient elastography was performed at 24 and 48 weeks from EOT. The FIB-4 index and the

1
2
3 aspartate aminotransferase (AST) to platelet ratio index (APRI) were calculated at baseline
4 and 24 and 48 weeks after EOT on fasting blood samples. The following formulas were
5 used. FIB-4=[age (years) x AST (IU/L)]/[platelets ($10^9/L$) x alanine aminotransferase
6 (ALT)^{1/2} (IU/L)]; a score of <1.45 and >3.25 should identify patients who, respectively, have
7 moderate or significant fibrosis [11]. APRI=[AST (IU/L)/upper limit of normal (IU/L)] x
8 100/platelets ($10^9/L$); severe fibrosis was considered unlikely with an APRI ≤ 0.7 and
9 cirrhosis likely with an APRI ≥ 1 [12]. Upper limits of normal for our laboratory are: ALT 40
10 IU/L for male and 35 IU/L for female; AST 45 IU/L for male and 30 IU/L for female.
11
12
13
14
15
16
17
18
19
20
21 Survival data were collected on May 31, 2016.
22
23
24

25 **Study endpoints**

26
27 Primary endpoints of the study were survival and clinical outcome of patients who had
28 achieved a sustained virological response at week 24 after EOT (SVR24). To this purpose
29 we considered the variations from baseline to weeks 24 and 48 of: i) liver function
30 parameters; ii) non-invasive tests of fibrosis (APRI, FIB-4, transient elastography).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

40 **Statistical analysis**

41
42
43 Categorical variables were represented as n (%) and compared using Fisher's exact test.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 Prism[®] version 6 (GraphPad Software Inc., La Jolla, CA, US) and IBM SPSS version 21
4
5 (New York, NY, US).
6
7
8

9 10 RESULTS

11 Of the 126 patients who entered the study, 118 received sofosbuvir and ribavirin for 24
12 weeks and 8 were treated with sofosbuvir, simeprevir and ribavirin for 12 weeks. In the
13 former group, 116 completed the full course of therapy; 2 patients died while on treatment
14 (on day 93 and 151), 4 following the EOT (on day 41, 143, 166 and 328). The median
15 follow-up of the surviving patients after EOT was 461 days (range 278-515 days).
16
17
18
19

20 All patients except 1 were Caucasian. Forty-seven percent of the grafts came from donors
21 ≥ 65 year old and/or with macrovesicular steatosis $\geq 15\%$ (suboptimal graft) [13], 8% from
22 hepatitis B core antibody positive and 7.1% from HCV antibody positive donors.
23
24
25
26
27
28

29 Two patients had been treated with a first-generation HCV protease-inhibitor before LT.
30 The baseline stage of hepatic fibrosis (F) was evaluated in 28 patients by liver biopsy
31 according to Metavir score (3 F3, 25 F4), in 12 patients by combined liver biopsy and
32 transient elastography (12 F4) and in 86 patients by transient elastography only (27 F3
33 and 59 F4). The median LS was: 11 kPa [interquartile 10.1-12] in the F3 group and 21.8
34 kPa [17-34.8] in the F4 group. Thirty-four patients had diabetes mellitus, 33 were insulin
35 dependent at the beginning of antiviral therapy.
36
37
38
39
40
41
42
43
44

45 The 8 patients treated with sofosbuvir, simeprevir and ribavirin were immunosuppressed
46 with tacrolimus. The HCV genotype was 1a in two and 1b in six. Seven patients had
47 fibrosis Metavir F3 and 1 F4 (Child A5, MELD 7), with median HCV RNA 6.56 log₁₀ IU/mL.
48
49
50
51 Further demographic and baseline characteristics are presented in **Table 1**.
52
53

54 Four weeks after antiviral therapy was started, a statistically significant decrease was
55 observed in the AST and ALT median values from 67 IU/L [45-114] to 24 IU/L [18-33], p
56 < 0.001 , and 58 IU/L [40-100] to 18 IU/L [13-26], $p < 0.001$, respectively. Transaminase
57
58
59
60

1
2
3 values normalized (**Figure S1**) and remained normal throughout the follow-up in all
4
5 eradicated patients but nine, who had persistently elevated enzymes (less than twice
6
7 upper limit of normal). Six of these latter patients underwent a liver biopsy which showed
8
9 minimal histological changes without evidence of rejection.

10
11 The overall SVR24 rate was 81.0% (102/126 patients, 95% confidence interval 73.2-86.9)
12
13 by intention to treat (ITT) analysis. The SVR24 rate was significantly higher in F3
14
15 compared with F4 patients (30/30, 100% vs 72/96, 75%, $p=0.001$); in patients tolerating
16
17 $\geq 80\%$ of the full weight-based ribavirin dose ($n=104$) compared with those tolerating $<80\%$
18
19 of the dose ($n=22$) (85.6% vs 59.0%, $p=0.01$) and in patients with preserved liver function
20
21 (MELD ≤ 11 and Child $\leq A6$, according to ROC curves) (**Figure S2**).

22
23
24 Two cirrhotic patients who became HCV RNA negative on therapy, died for multiresistant
25
26 bacteria-related septic shock; two others died of liver failure after the EOT: one, 68 years
27
28 old, had achieved a sustained virological response at week 4 after EOT, the other, 44
29
30 years old, had achieved SVR12 and was on the list for retransplantation.

31
32
33 Twenty patients experienced a relapse of HCV (17 at week 4, 2 at week 12 and 1 at week
34
35 24 of follow-up; the latter cleared HCV RNA at week 4 on therapy and normalized
36
37 transaminases at week 1). All relapsers were cirrhotic (9 patients Child A, 10 Child B and 1
38
39 Child C). They had a median pre-treatment MELD of 13 and had received sofosbuvir and
40
41 ribavirin; the majority of them were *IL28B* non-C/C genotype (80%) and experienced to
42
43 previous antiviral therapy (65%) (**Tables S1 and S2**). Basal median LS was 28.0 kPa in
44
45 the relapsers and 20.4 kPa in the cirrhotics who achieved viral eradication ($p=0.01$). APRI
46
47 and FIB-4 were significantly higher in relapsers compared with responders at baseline
48
49 (3.27 vs 1.92 and 8.45 vs 5.95, respectively; $p < 0.01$ for both) (**Table 2**).

50
51
52 From baseline to EOT, the median Child improved in relapsers from B7 to A6 ($p=0.014$),
53
54 while the median MELD remained 13. Two patients died at 138 and 160 days after relapse
55
56 due to progressive end-stage liver disease. Seventeen patients started a second treatment
57
58
59
60

1
2
3 course, at a median of 17 weeks (range 5-43 weeks) from the relapse. No significant
4
5 variation in liver function tests was observed between relapse and retreatment. One
6
7 patient refused retreatment.
8

9
10 Overall, in the cirrhotic group, 20 patients (20.8%) had a stable MELD from baseline to the
11
12 last available follow-up visit and 43 (44.8%) improved the score of at least 1 point; 46
13
14 patients (47.9%) had a stable Child and 35 (36.5%) improved the score of at least 1 point.
15
16

17 18 **Clinical outcomes in patients who achieved viral eradication**

19
20 In the F3 patients, liver and kidney function remained normal (**Table S3**). APRI and FIB-4
21
22 were significantly lower at week 24 after EOT, compared with pre-treatment median values
23
24 (1.07 to 0.41, $p < 0.001$, and 3.26 to 2.08, $p < 0.001$, respectively); these indexes remained
25
26 stable in the 28 patients who reached 48 weeks of follow-up (**Figure 1, Panels A and C**).
27
28

29
30 LS (available in 27 patients) improved from 11.0 kPa [10.1-12.0] to 7.7 kPa [6.6-10.2], p
31
32 < 0.001 , at week 24 and remained stable at week 48 (7.8 kPa [7.0-10.6], $p = 0.65$ vs week
33
34 24) (**Figure 2, Panel A**). In 18 patients (66.7%) LS decreased below the 9.5 kPa cut-off for
35
36 F3 at week 48.
37

38
39 At week 24 after EOT, the 72 F4 patients who had eradicated HCV, exhibited a significant
40
41 improvement in platelets count, bilirubin and albumin levels, degree of ascites and Child
42
43 score at pair wise comparison with baseline values [the rate of Child A was 77.8% (56/72)
44
45 at baseline and 88.9% (64/72) at week 24 of follow-up]; kidney function and MELD score
46
47 did not vary. Seventy-one of the 72 responders reached 48 weeks of follow-up and
48
49 showed a further significant increase in platelets count; albumin, ascites, and Child score
50
51 [93% (66/71) Child A] remained stable (**Table 3**).
52
53

54
55 Both APRI and FIB-4 decreased significantly at week 24 after EOT compared with baseline
56
57 values (1.92 to 0.55, $p < 0.001$, and 5.95 to 3.15, $p < 0.001$, respectively), and further
58
59
60

1
2
3 decreased at week 48, compared with 24 week values (APRI 0.51, $p < 0.001$; FIB-4 3.12, p
4 < 0.001) (**Figure 1, Panels B and D**). Fifty-one of the 72 patients underwent transient
5 elastography at baseline and at SVR24; the median LS improved from 20.4 kPa [16.0-
6 33.8] to 17.5 kPa [11.1-25.7], $p < 0.001$ (**Figure 2, Panel B**). Fifty patients underwent
7 transient elastography also at week 48 after EOT; the median LS (14.0 kPa [10.0-21.3])
8 significantly decreased compared with week 24 ($p = 0.001$); in 21 of them (42%) the LS fell
9 below the 12.5 kPa cut-off.
10
11

12 In 39 (50.6%) of the 77 F3-F4 responders pooled together, the fibrosis stage had
13 regressed in transient elastography by at least one Metavir stage at week 48 after EOT.
14
15

16 No patients developed hepatocellular carcinoma in the period of observation.
17

18 Thirteen out of the 20 cirrhotic responders with large oesophageal varices at baseline,
19 underwent a second 48 week follow-up endoscopy; no change in the size of varices was
20 observed.
21
22

23 Safety

24 AE are summarized in **Table S4**.
25

26 During therapy, seven cirrhotic patients were hospitalised: two patients for grade 3
27 encephalopathy, two for severe variceal bleeding and three for sepsis in decompensated
28 liver disease. Six cirrhotic patients died of complications of end-stage liver disease,
29 unrelated to antiviral therapy.
30
31

32 Three patients discontinued ribavirin for less than 1 week due to diffuse macular skin rash
33 and no one discontinued therapy permanently due to AE.
34
35

36 Because of anemia and/or compromised renal function, 34.1% (43/126) of the patients
37 were treated with a non weight-based escalating dose of ribavirin, starting from 400 mg
38 daily and 11.1% (14/126) required dosage reduction; however, 82.5% (104/126) received
39 at least 80% of the weight-based dosage. Median daily ribavirin dose was 1000 mg from
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 baseline to EOT and median haemoglobin level declined from 12.8 g/dL at baseline to 10.9
4
5 g/dL at week 4 and remained stable around 10.8 g/dL from week 8 to week 24 (**Figure**
6
7 **S3**). In 60 patients (47.6%) we measured at least one haemoglobin level of less than 10
8
9 g/dL and in 12 (9.5%) of less than 8.5 g/dL; 45 patients (35.7%) received epoetin and 14
10
11 (11.1%) required blood transfusion.

12
13
14 Minimal dose adjustments in the calcineurin inhibitors were required throughout the
15
16 treatment in 64% of the patients (27% increased, 12% decreased and 25% both
17
18 decreased and increased the dose) to maintain stable trough levels. No biopsy-proven
19
20 acute rejection occurred.
21
22

23 24 25 **DISCUSSION**

26
27 The advent of highly effective and well tolerated DAAs against the HCV is revolutionizing
28
29 the outcome of LT for hepatitis C. In this setting, early treatment after surgery is expected
30
31 to be the most cost-effective strategy for patients who are still viremic at LT [10, 14],
32
33 nevertheless DAAs are providing rescue also to residual cohorts of re-infected transplant
34
35 recipients who developed advanced HCV disease [7, 8, 15]. When sofosbuvir became
36
37 available in Italy in June 2014, these patients received priority access to the new therapy
38
39 through a compassionate use program. A majority were treated with sofosbuvir and
40
41 ribavirin; a small minority received the combination of sofosbuvir, ribavirin and simeprevir,
42
43 which became available almost at the end of the enrollment period.
44
45

46
47 After a median follow-up of 461 days from EOT, 102 (81%) of our 126 patients are free of
48
49 HCV and clinically stable. SVR was obtained also in a high proportion (95%) of the 21
50
51 patients with genotype 3, though this genotype is the most difficult to treat in the ordinary
52
53 clinical context. All treatment failures, excluding deceased patients, were due to virologic
54
55 relapses and all relapses, except one, occurred within the first 12 weeks after EOT.

56
57
58 Response to therapy was influenced by the stage of fibrosis and by intolerance to ribavirin:
59
60

1
2
3 75% of the patients with cirrhosis achieved an SVR compared to 100% of those with F3
4 fibrosis and among the 22 patients who tolerated less than 80% of the optimal ribavirin
5 dosage, only 59% obtained an SVR. As expected, anemia was the main complication of
6 ribavirin.
7
8
9

10
11 Considering the higher proportion of patients with cirrhosis in this study, our results appear
12 better than the 70% rate of SVR12 reported by Charlton [16] in a smaller series of 40
13 patients recruited in a multicenter study, of whom only 40% were cirrhotics; possibly the
14 management of the patients in a single center adopting a common approach may lead to
15 more uniform results. Though our results are distinctly better than the 43% response
16 reported by Forns et al [7], their series included a mixed population of compensated and
17 decompensated cirrhotics in which a substantial number of patients had a higher MELD
18 score and more severe disease than our patients.
19
20
21
22
23
24
25
26
27
28

29
30 There were in our study six deaths due to complications of the liver disease, two occurring
31 in patients who had cleared the HCV. The deceased patients had a higher MELD score,
32 ranging from 14 to 19, in confirmation that a deteriorated liver function may prevent clinical
33 improvement despite the antiviral efficacy of treatment [17]; vice versa a preserved liver
34 function expressed by a Child Pugh score ≤ 6 and a MELD ≤ 11 was associated with SVR.
35
36
37
38
39
40 In our 72 cirrhotic responders, SVR24 was associated with the normalization of
41 aminotransferases in almost all patients, accompanied by a decrease of bilirubin and an
42 increase of albumin levels; renal function deteriorated in none and ascites disappeared in
43 three quarters of cases. The platelet count increased throughout therapy, presumably
44 related to the administration of epoetin and to an increased production of endogenous
45 erythropoietin, secondary to ribavirin-induced anemia [18]. The platelet number diminished
46 to baseline values at week 12 post-therapy, but then climbed back significantly at week 24
47 and further increased at week 48; this trend and the regression of ascites might be
48
49
50
51
52
53
54
55
56
57
58
59
60 expression of an initial reduction in portal hypertension.

1
2
3 The APRI and FIB-4 indexes significantly improved throughout the follow-up; as
4
5 aminotransferases and platelets are major components for their calculation, the
6
7 improvement can be explained by the normalization of the enzymes and by the increase in
8
9 the platelet count.

10
11 LS values were significantly reduced at the 6th month of follow-up; this early improvement
12
13 presumably resulted for a large extent from the decrease of inflammation and edema
14
15 which may artificially alter elastography. Interestingly, however, LS values showed a further
16
17 significant decrease during the subsequent 6 month follow-up in patients with cirrhosis.

18
19 Considering that artefacts due to liver inflammation could no longer be implicated, it is
20
21 plausible that the observed continuing decrease of LS after the SVR24 corresponded to a
22
23 genuine progressive reduction of fibrosis. In agreement with previous findings of fibrosis
24
25 reversion in non-transplant patients with HCV cirrhosis who responded to interferon-
26
27 therapy [19-21], our data would suggest that regression of fibrosis starts early and may
28
29 become already measureable by transient elastography in the first year after therapy.

30
31
32 In conclusion, our experience in a large single center LT cohort of advanced recurrent HCV
33
34 disease, confirms the major therapeutic impact of sofosbuvir with ribavirin, extending also
35
36 to difficult-to-treat genotype 3 patients.

37
38
39 We acknowledge that a new wave of more efficacious DAA combinations is now available
40
41 to treat hepatitis C [8, 15, 22]. Nevertheless, this study provides a paradigm of the
42
43 excellent clinical outcome and of the potential for disease reversibility after successful DAA
44
45 therapy in the transplant setting.

46 47 48 49 50 51 **ACKNOWLEDGEMENTS**

52
53
54 No funding was obtained for this study.
55
56
57
58
59
60

REFERENCES

- [1] Adam R, Karam V, Delvart V. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol* 2012;57:675-688.
- [2] Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. *Gastroenterology* 2002;122:889–896.
- [3] Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. *Gastroenterology* 2012;142:1373-1383.
- [4] Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. *J Hepatol* 2008;49:274-287.
- [5] Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. *J Hepatol* 2014;60:78-86.
- [6] EASL recommendations on treatment of hepatitis C 2015. *J Hepatol* 2015;63:199-236.
- [7] Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. *Hepatology* 2015;61:1485-1494.
- [8] Brown RS Jr, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR Jr, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCV-TARGET. *Liver Transpl* 2016;22:24-33.
- [9] Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol* 2008;48:835-847.
- [10] Romagnoli R, Martini S, Tandoi F, Dell Olio D, Magistroni P, Bertinetto FE, et al. Early reduced liver graft survival in hepatitis C recipients identified by two combined

1
2
3 genetic markers. *Transpl Int* 2016; doi: 10.1111/tri.12795.

4
5 [11] Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al.
6
7 FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with
8
9 liver biopsy and fibrotest. *Hepatology* 2007;46:32-36.

10
11 [12] Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS,
12
13 et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in
14
15 patients with chronic hepatitis C. *Hepatology* 2003;38:518-526.

16
17 [13] Salizzoni M, Franchello A, Smedile A, David E, Barbui A, Torrani M, et al. Marginal
18
19 grafts: finding the correct treatment for fatty livers. *Transpl Int* 2003;16:486-493.

20
21 [14] Russo FP, Zanetto A, Burra P. Timing for treatment of HCV recurrence after liver
22
23 transplantation: the earlier the better. *Transpl Int* 2016;29:694-697.

24
25 [15] Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, et al. Ledipasvir
26
27 and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver
28
29 disease. *Gastroenterology* 2015;149:649-659.

30
31 [16] Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofosbuvir
32
33 and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver
34
35 transplantation. *Gastroenterology* 2015;148:108-117.

36
37 [17] Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, et al.
38
39 Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity
40
41 but no clinical benefit if treatment is given late. *Dig Liver Dis* 2014;46:923-927.

42
43 [18] Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, et al. Anemia and
44
45 thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. *J*
46
47 *Gastroenterol* 2012;47:1228-1237.

48
49 [19] Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact
50
51 of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic
52
53 hepatitis C. *Gastroenterology* 2002;122:1303-1313.
54
55
56
57
58
59
60

1
2
3 [20] EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver
4 disease severity and prognosis. European Association for the Study of the Liver. J Hepatol
5 2015;63:237-264.
6
7

8
9 [21] D'Ambrosio R, Aghemo A, Fraquelli M, Rumi MG, Donato MF, Paradis V, et al. The
10 diagnostic accuracy of Fibroscan® for cirrhosis is influenced by liver morphometry in HCV
11 patients with a sustained virological response. J Hepatol 2013;59:251-256.
12
13

14 [22] Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al. HCV
15 Research UK. Cohort study of the impacts of direct acting antiviral therapy in patients with
16 chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;64:1224-1231.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic and baseline characteristics of recipients and donors

Recipient features (N=126)	
Age (years)	60 [54-66]
Male	99 (78.6%)
Body Mass Index (Kg/m²)	24.6 [22.5–26.9]
25-OH vitamin D^A (<20 ng/mL)	71 (59.2%)
HLA-DRB1*11 positive phenotype	34 (27.0%)
<i>IL28B</i> genotype	
rs 12979860 C/C	32 (25.4%)
rs 8099917 T/T	59 (46.8%)
Previous antiviral treatment	83 (65.9%)
Antiviral treatment after LT	57 (45.2%)
Immunosuppressive drug	
CsA – Tac – MMF – other	50 (39.7%) – 56 (44.4%) – 56 (44.4%) – 5 (4.0%)
Time since LT (years)	4.3 [2.3–7.2]
HCV genotype	
1a - 1b - 1 (unspecified)	17 (13.5%) – 70 (55.6%) – 6 (4.8%)
2 - 3 – 4	6 (4.8%) – 21 (16.7%) – 6 (4.8%)
Baseline HCV RNA (log₁₀ IU/mL)	6.40 [6.10–6.66]
≥ 10 ⁶ IU/mL	101 (80.2%)
Corresponding Metavir fibrosis stage	
F3 – F4	30 (23.8%) – 96 (76.2%)
Haemoglobin (g/dL)	12.8 [11.4–14.4]
Platelets count (10⁹/L)	99 [67-140]
Liver enzymes (IU/L)	
Aspartate aminotransferase	60 [40-101]
Alanine aminotransferase	69 [45-116]
γ-Glutamyltransferase	75 [41-152]

Total bilirubin (mg/dL)	1.1 [0.7–1.8]
INR	1.07 [0.98–1.22]
Albumin (g/dL)	3.9 [3.6–4.3]
eGFR* (mL/min)	70 [54-87]
MELD score[§]	10 [8-13]
Child class[§] A – B – C	65 (67.7%) – 27 (28.1%) – 4 (4.2%)
Ascites[§]	38 (39.6%)
Encephalopathy[§]	12 (12.5%)
Presence of varices[§]	26 (27.1%)
Donor features (N=126)	
Age (years)	62 [50–71]
Male	69 (54.8%)
Split liver graft	2 (1.6%)
Graft quality[^] suboptimal[#]	57 (47.5%)
Cold ischemia time (minutes)	486 [424–545]
Donor/Recipient match	
D-MELD	982 [666–1303]

Numerical variables are expressed as median [Q1-Q3]

Categorical variables are expressed as numbers (prevalence, %)

[^]6 missing data

^{*}Chronic Kidney Disease Epidemiology Collaboration equation

[§]In 96 cirrhotic patients

[#]According to Salizzoni et al, Transpl Int 2003

Abbreviations: CsA, cyclosporine; D-MELD, donor age x recipient MELD; eGFR, estimated glomerular filtration rate; F, fibrosis; HCV, hepatitis C virus; HLA, human leukocyte antigen; *IL28B*, *Interleukin 28B*; LT, liver transplantation; MELD, Model for End-stage Liver Disease; MMF, mycophenolate mofetil; Tac, tacrolimus.

Table 2. Liver function tests and non-invasive markers of fibrosis at baseline and at the end of therapy in responder versus relapser cirrhotic patients

BASELINE	Responders (n=72)	Relapsers (n=20)	p[#]
APRI	1.92 [1.00-3.27]	3.27 [1.72-5.51]	0.007
FIB-4	5.95 [3.60-11.10]	8.45 [7.17-16.08]	0.009
Liver stiffness* (kPa)	20.4 [16.0-33.8]	28.0 [21.6–44.4]	0.01
Child score	5 [5-6]	7 [6-8]	0.002
MELD score	10 [8-12]	13 [9-16]	0.02
EOT	Responders (n=72)	Relapsers (n=20)	p[#]
APRI	0.46 [0.29-0.76]	0.83 [0.57-1.22]	0.02
FIB-4	3.25 [1.90-4.30]	4.80 [3.71-7.42]	0.01
Liver stiffness* (kPa)	17.5 [11.1-25.7]	23.4 [18.3-39.0]	0.09
Child score	5 [5-6]	6 [5-7]	0.19
MELD score	11 [9-14]	13 [11-17]	0.05

Numerical variables are expressed as median [Q1-Q3]

*Liver stiffness was available at baseline in 51 responders and 17 relapsers; at EOT in 51 responders and 13 relapsers

[#]p-values calculated according to Wilcoxon test for paired data

Abbreviations: APRI, AST to platelet ratio index; EOT, end of therapy; kPa, kilopascal; MELD, Model for End-stage Liver Disease.

Table 3. Clinical and biochemical variations in long-term responder cirrhotic patients

	Baseline	EOT	SVR12	SVR24	SVR48	p[^]	p[§]
	(N=72)	(N=72)	(N=72)	(N=72)	(N=71[°])		
AST (IU/L)	69 [47-97]	23 [20-28]	27 [22-35]	24 [18-32]	21 [18-28]	<0.001	0.13
ALT (IU/L)	59 [41-90]	15 [11-23]	18 [14-27]	16 [12-25]	17 [12-27]	<0.001	0.02
Bilirubin (mg/dL)	1.1 [0.8-1.5]	1.4 [1.1-2.2]	0.9 [0.6-1.2]	0.8 [0.6-1.2]	0.9 [0.6-1.1]	<0.001	0.74
INR	1.06 [0.99-1.20]	1.11 [1.07-1.24]	1.09 [1.02-1.24]	1.08 [1.02-1.22]	1.11 [1.07-1.23]	0.03	0.007
Albumin (g/dL)	3.9 [3.6-4.3]	4.1 [3.8-4.4]	4.1 [3.7-4.3]	4.2 [3.8-4.4]	4.3 [4.0-4.5]	0.02	0.31
Creatinine (mg/dL)	1.1 [0.9-1.3]	1.1 [0.9-1.3]	1.0 [0.9-1.3]	1.1 [1.0-1.3]	1.1 [0.9-1.3]	0.36	0.12
eGFR* (mL/min)	68 [52-84]	64 [52-80]	67 [53-83]	63 [52-78]	62 [52-82]	0.26	0.25
Platelets (10⁹/L)	99 [65-134]	131 [86-185]	99 [64-133]	108 [72-142]	112 [68-144]	0.002	0.01
Ascites	22 (30.6%)	12 (16.7%)	8 (11.1%)	7 (9.7%)	7 (9.9%)	0.003	>0.99
Encephalopathy	5 (6.9%)	4 (5.6%)	3 (4.2%)	3 (4.2%)	2 (2.8%)	0.72	>0.99
MELD score	10 [8-12]	11 [9-14]	9 [8-11]	9 [8-11]	10 [8-11]	0.34	0.92
Child score	5 [5-6]	5 [5-6]	5 [5-6]	5 [5-5]	5 [5-5]	<0.001	0.68

Numerical variables are expressed as median [Q1-Q3]

Categorical variables are expressed as numbers (prevalence,%)

p-values calculated according to Wilcoxon test for paired data for numerical variables and according to Fisher's exact test for categorical variables

[°]71 out of 72 cured patients reached 48 weeks of follow-up after therapy

*Chronic Kidney Disease Epidemiology Collaboration equation

[^]Baseline versus SVR24

[§]SVR24 versus SVR48

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; EOT, end of therapy; MELD, Model for End-stage Liver Disease; SVR12, sustained virological response at week 12 after end of therapy; SVR24, sustained virological response at week 24 after end of therapy; SVR48, sustained virological response at week 48 after end of therapy.

FIGURE LEGENDS

Figure 1. Variations of APRI (Panels A and B) and FIB-4 (Panels C and D) from baseline to weeks 24 and 48 after therapy, in F3 and F4 long-term responders. APRI, AST to platelet ratio index; F, fibrosis according to Metavir; SVR24, sustained virological response at week 24 after therapy; SVR48, sustained virological response at week 48 after therapy.

Figure 2. Variations of liver stiffness from baseline to weeks 24 and 48 after therapy in F3 (Panel A) and F4 (Panel B) long-term responders. F, fibrosis according to Metavir; kPa, kilopascal; SVR24, sustained virological response at week 24 after therapy; SVR48, sustained virological response at week 48 after therapy.

Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Impact of Viral Eradication with Sofosbuvir-based Therapy on the Outcome**
4
5 **of Post-Transplant Hepatitis C with Severe Fibrosis**
6
7

8
9 Silvia Martini,¹ Marco Sacco,¹ Silvia Strona,¹ Daniele Arese,¹ Francesco Tandoi,²
10
11 Dominic Dell Olio,³ Davide Stradella,¹ Donatella Cocchis,² Stefano Mirabella,²
12
13 Giorgia Rizza,² Paola Magistroni,³ Pamela Moschini,³ Antonio Ottobrelli,¹
14

15
16 Antonio Amoroso,³ Mario Rizzetto,¹ Mauro Salizzoni,²
17

18
19 Giorgio M. Saracco,¹ Renato Romagnoli²
20

21
22
23 ¹Gastrohepatology Unit

24
25 ²Liver Transplantation Center, General Surgery Unit 2U
26

27
28 ³Regional Transplantation Center, Piedmont
29

30
31 AOU Città della Salute e della Scienza di Torino, University of Turin, Italy
32
33
34
35

36 **Correspondence information**
37

38 Silvia Martini, MD
39

40 Gastrohepatology Unit, AOU Città della Salute e della Scienza di Torino
41

42 Corso Bramante, 88 - 10126 Turin - Italy
43

44
45 Phone: +39 011 6335928; fax: +39 011 6334014
46

47 E-mail address: sivima21@hotmail.com
48
49

50
51
52 Electronic word count for main body of the manuscript: 44684337.
53

54 Number of figures: 24. Number of tables: 32.
55
56
57
58
59
60

List of abbreviations in the order of appearance:

HCV, hepatitis C virus; LT, liver transplantation; Peg-IFN, pegylated-interferon; SVR, sustained virological response; SVR12, sustained virological response at week 12 after the end of treatment; DAAs, direct-acting antiviral agents; LS, liver stiffness; kPa, kilopascal; EOT, end of therapy; *IL28B*, *Interleukin 28B*; HLA, human leukocyte antigen; AE, adverse event; AST, aspartate aminotransferase; APRI, AST to platelet ratio index; ALT, alanine aminotransferase; SVR24, sustained virological response at week 24 after the end of treatment; ROC, receiver operating characteristic; MELD, Model for End-stage Liver Disease; F, fibrosis; ITT, intention to treat. ~~AUC, area under the curve.~~

Conflict of interest

MR is an Advisory Board member for AbbVie, BMS, Gilead, Janssen, MSD.

GMS is an Advisory Board member for AbbVie, Gilead and MSD.

SM is a Regional Advisory Board member for Gilead.

The other Authors who have taken part in this study declared no conflict of interest.

Financial support

This work was unsupported.

ABSTRACT

Background & Aims. Several studies report **have shown** that the new direct-acting-antivirals (DAAs) induce **maintain** viral **their efficacy** eradication also in liver transplant (LT) recipients with severe HCV recurrence. **We determined** The **the clinical** impact of Sofosbuvir/Ribavirin **in LT** therapy **through the changes in** α liver function and α fibrosis progression **state** at 24 and 48 weeks after treatment was evaluated.

Methods. Between 06/2014 and 07/2015, 126 patients (30 F3, 96 F4 Metavir stage) were enrolled to receive sofosbuvir+ribavirin (24 weeks, 118 patients) or sofosbuvir+simeprevir+ribavirin (12 weeks, 8 patients); treatment was initiated at a median time of 4.3 years from LT. Median follow-up after therapy completion was 461 days.

Results. All 30 F3 patients achieved a sustained virological response at week 24 after treatment (SVR24), and showed a distinct amelioration of the AST-to-platelet-ratio-index (APRI), FIB-4 and liver stiffness at elastography by week 24 post-therapy, which were maintained at week 48.

Of the 96 F4 cirrhotic patients, 72 (75%) achieved SVR24 accompanied by a significant improvement of liver function, which was maintained at week 48 (Child B-C 22% baseline, 11% week 24, 7% week 48); APRI, FIB-4, and liver stiffness further improved significantly between week 24 and 48 of follow-up. Among the 77 responders (27 F3, 50 F4) who underwent elastography at baseline and at the end of follow-up, 39 (50.6%; 18 F3, 21 F4) exhibited a regression in fibrosis stage. *Conclusion.* At about one-year from the completion of successful sofosbuvir-based therapy, patients with post-LT HCV and severe fibrosis experienced a long-term liver function improvement accompanied by a regression of fibrosis stage in half of them.

Keywords

Liver transplantation; HCV recurrence; direct-acting antivirals; non-invasive fibrosis tests; survival.

Key point box

- 126 patients with post liver transplant HCV and severe fibrosis (30 F3 **and** 96 F4 Metavir) received a sofosbuvir-based antiviral therapy. **The M**edian follow-up after therapy was 461 days.
- All **the** 30 F3 patients and ~~72/96~~ **72 of the 96** (75%) cirrhotics **(75%)** ~~are currently alive and~~ achieved a sustained virological response at week 24 after treatment.
- HCV-**eradicated** ~~cured~~ patients showed a distinct amelioration in AST-to-platelet-ratio-index, FIB-4 and liver stiffness at week 24 after therapy, which persisted in F3 patients and further improved in F4 ones at week 48.
- **In transient elastography, the fibrosis stage regressed in half of the HCV-eradicated**
~~Overall, a fibrosis stage regression evaluated by transient elastography, occurred in half of the patients at week 48 after therapy.~~

INTRODUCTION

Hepatitis C virus (HCV) is the leading cause of cirrhosis and hepatocellular carcinoma and the most common indication for liver transplantation (LT) in Europe and United States [1].

Infection recurs almost universally in patients who have detectable serum HCV RNA at LT and it is the main cause of graft failure and patient death [2]. Successful HCV eradication is associated with reduced disease progression, and improved liver allograft and recipient survival [3].

Until few years ago, pegylated-interferon (Peg-IFN) with ribavirin was the only treatment for HCV recurrence post-LT; however its use was limited by poor efficacy and beset with significant adverse events [4]. The addition of first generation protease inhibitors, boceprevir and telaprevir, doubled the rates of sustained virological response (SVR) at 12 weeks (SVR12) in HCV genotype 1, but was aggravated by unacceptable toxicity and drug-drug interactions [5]. A major breakthrough has been the advent of second generation direct-acting antiviral agents (DAAs), which interact with different HCV functions and have markedly improved antiviral efficacy and tolerability [6], leading to HCV eradication also in patients with severe recurrent hepatitis C after LT.

The therapeutic potential of the prototype sofosbuvir was quickly perceived; the combinations of sofosbuvir with ribavirin ± Peg-IFN and of sofosbuvir with simeprevir ± ribavirin were reported in early international studies to achieve 59% to 88% SVR12 rates [7, 8]. A sofosbuvir compassionate use program was activated in Italy between June 2014 and December 2014; simeprevir became available later, in February 2015.

The primary target of early studies was the virologic efficacy and the tolerability of DAAs in order to meet the urgent demand from transplant patients. In this single-center study, we report the clinical outcome of therapy in a large series of patients with severe fibrosis due to hepatitis C recurrence; the majority were treated with sofosbuvir plus ribavirin, a minority with sofosbuvir plus simeprevir plus ribavirin. We focused on the changes in liver function

1
2
3 parameters and in non-invasive tests of fibrosis up to 48 weeks after the end of successful
4
5 treatment. These studies had short follow-ups and did not deal with the long-term clinical-
6
7 outcome of LT patients who had responded to therapy.
8

9
10 In this single-center study, we collected a large series of patients with post-transplant
11
12 severe fibrosis due to hepatitis C recurrence; the majority were treated with sofosbuvir plus
13
14 ribavirin, a minority with sofosbuvir plus simeprevir plus ribavirin. We report the virologic-
15
16 results and focus on the changes observed in liver function parameters and in non-
17
18 invasive tests of fibrosis up to 48 weeks after the end of successful therapy.
19

20 21 22 **PATIENTS AND METHODS**

23 24 **Study population**

25
26
27 Out of 273 surviving HCV recipients with persistent viremia following LT performed in Turin
28
29 (Italy) since January 2000, between June 2014 and May 2015 we enrolled 126 patients
30
31 with recurrent hepatitis C who exhibited a Metavir staging score ≥ 3 , and a creatinine
32
33 clearance ≥ 30 mL/min. The severity of fibrosis was determined within 6 months from
34
35 treatment by liver biopsy or by transient elastography [liver stiffness (LS) cut-off values of
36
37 9.5 kilopascal (kPa) and 12.5 kPa corresponding, respectively, to Metavir F3 and F4
38
39 fibrosis stages] [9]. Only transient elastography measurements with a success rate of at
40
41 least 60% were considered valid.
42
43

44
45 From June 2014 to December 2014 patients were treated in the context of the sofosbuvir
46
47 national compassionate use program; each treatment was approved by the local ethic
48
49 committee (Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di
50
51 Torino—A.O. Ordine Mauriziano—A.S.L. TO1) and the patients provided written informed
52
53 consent. By the Italian legislation, Regional Transplantation Centers are the lawful
54
55 custodians of the recipient/donor biomedical data for clinical and for research purposes. All
56
57 study procedures were compliant with the ethical standards of the 2000 Declaration of
58
59
60

1
2
3 Helsinki as well as the Declaration of Istanbul 2008.

4
5 The demographic and baseline characteristics of the study population and their donors are
6
7 shown in Table 1.
8
9

10 11 **Study protocol**

12
13 The treatment regimens consisted of sofosbuvir 400 mg once daily and ribavirin twice daily
14
15 (at a dose of 1000 mg daily with body weight <75 kg, or 1200 mg daily with body weight
16
17 ≥75 kg, adjusted according to haemoglobin level and renal function) for 24 weeks, or
18
19 sofosbuvir 400 mg once daily, ribavirin twice daily (weight-based) and simeprevir 150 mg
20
21 once daily for 12 weeks. Epoetin-alfa at 20,000-40,000 units/week was administered
22
23 subcutaneously to patients with haemoglobin levels <10 g/dL.
24
25

26
27 Patients underwent clinical and laboratory assessment [HCV RNA by polymerase chain
28
29 reaction technique with AmpliPrep[®]/COBAS TaqMan[®] HCV version 2 (Roche Molecular
30
31 Systems, Inc., Branchburg, NJ, US), complete blood cell count, liver and kidney function
32
33 tests, serum electrolytes, serum levels of immunosuppressive drugs] at baseline, weekly
34
35 for the first month, then monthly while on treatment and at 1, 3, 6 and 12 months after the
36
37 end of therapy (EOT). No viral resistance monitoring was performed.
38
39

40
41 At baseline, all patients were tested for HCV genotype (reverse hybridization line probe
42
43 assay, INNO-LIPA, Innogenetics, Ghent, Belgium), *Interleukin 28B (IL28B)* rs12979860
44
45 C/T and rs8099917 T/G polymorphisms (Custom TaqMan[®] Allelic Discrimination Kit, Life
46
47 Technologies Applied Biosystems[®], Thermo Fisher Scientific, Waltham, MA, US) and
48
49 serum 25-OH vitamin D level (fully automated chemiluminescence immunoassay, ADVIA
50
51 Centaur[®] Vitamin D Total assay, Siemens Healthcare Diagnostics Inc., Tarrytown, NY,
52
53 USA). Human leukocyte antigen (HLA) DRB1 typing was collected as well (performed
54
55 before transplant, by serology methods until 2006 and then by molecular low-resolution),
56
57 paying particular attention to HLA-DRB1*11 phenotype [10]. Adverse events (AE), drug
58
59
60

1
2
3 dose modifications, use of growth factors, blood transfusions, and need for hospitalisation
4
5 during treatment were recorded.
6

7
8 To assess the changes in fibrosis evolution in virological responders, transient
9
10 elastography was performed at 24 and 48 weeks from EOT. The FIB-4 index and the
11
12 aspartate aminotransferase (AST) to platelet ratio index (APRI) were calculated at baseline
13
14 and 24 and 48 weeks after EOT on fasting blood samples. The following formulas were
15
16 used. $FIB-4 = [age \text{ (years)} \times AST \text{ (IU/L)}] / [platelets \text{ (} 10^9/L) \times alanine \text{ aminotransferase}$
17
18 $(ALT)^{1/2} \text{ (IU/L)}]$; a score of <1.45 and >3.25 should identify patients who, respectively, have
19
20 moderate or significant fibrosis [11]. $APRI = [AST \text{ (IU/L)} / upper \text{ limit of normal (IU/L)}] \times$
21
22 $100 / platelets \text{ (} 10^9/L)$; severe fibrosis was considered unlikely with an $APRI \leq 0.7$ and
23
24 cirrhosis likely with an $APRI \geq 1$ [12]. Upper limits of normal for our laboratory are: ALT 40
25
26 IU/L for male and 35 IU/L for female; AST 45 IU/L for male and 30 IU/L for female.
27
28

29
30 Survival data were collected on May 31, 2016.
31
32

33 34 **Study endpoints**

35
36 Primary endpoints of the study were survival and clinical outcome of patients who had
37
38 achieved a sustained virological response at week 24 after EOT (SVR24). To this purpose
39
40 we considered the variations from baseline to weeks 24 and 48 of: i) liver function
41
42 parameters; ii) non-invasive tests of fibrosis (APRI, FIB-4, transient elastography).
43
44

45
46 Secondary endpoint was the safety of antiviral therapy.
47
48

49 50 **Statistical analysis**

51
52 Categorical variables were represented as n (%) and compared using Fisher's exact test.
53
54 Quantitative variables were shown as median (25th - 75th percentiles) and were compared,
55
56 as appropriate, by t-test (parametric data), by Mann-Whitney U test (non parametric,
57
58 unpaired data) or by Wilcoxon signed-rank test (non parametric, paired data). Receiver
59
60

operating characteristic (ROC) curve analyses were performed to obtain the best possible Model for End-stage Liver Disease (MELD) **and** Child scores., ~~and non-invasive fibrosis tests thresholds,~~ in order to identify beforehand those patients who achieved SVR24. Data elaboration was performed using Prism[®] version 6 (GraphPad Software Inc., La Jolla, CA, US) and IBM SPSS version 21 (New York, NY, US).

RESULTS

Of the 126 patients who entered the study, 118 received sofosbuvir and ribavirin for 24 weeks and 8 were treated with sofosbuvir, simeprevir and ribavirin for 12 weeks. In the former group, 116 completed the full course of therapy; 2 patients died while on treatment (on day 93 and 151), 4 following the EOT (on day 41, 143, 166 and 328). The median follow-up of the surviving patients after EOT was 461 days (range 278-515 days).

All patients except 1 were Caucasian. Forty-seven percent of the grafts came from donors ≥ 65 year old and/or with macrovesicular steatosis $\geq 15\%$ (suboptimal graft) [13], 8% from hepatitis B core antibody positive donors and 7.1% from HCV antibody positive **donors**.

Two patients had been treated with a first-generation HCV protease-inhibitor before LT. The baseline stage of hepatic fibrosis (F) was evaluated in 28 patients by liver biopsy according to Metavir score (3 F3, 25 F4), in 12 patients by combined liver biopsy and transient elastography (12 F4) and in 86 patients by transient elastography only (27 F3 and 59 F4). The median LS was: 11 kPa [interquartile 10.1-12] in the F3 group and 21.8 kPa [17-34.8] in the F4 group. Thirty-four patients had diabetes mellitus, 33 were insulin dependent at the beginning of antiviral therapy.

All **The** 8 patients treated with sofosbuvir, simeprevir and ribavirin were immunosuppressed with tacrolimus. The HCV genotype was 1a in two and 1b in six. Seven patients had fibrosis Metavir F3 and 1 F4 (Child A5, MELD 7), with median HCV RNA 6.56 log₁₀ IU/mL.

Further demographic and baseline characteristics are presented in **Table 1**.

Four weeks after antiviral therapy was started, a statistically significant decrease was observed in the AST and ALT median values from 67 IU/L [45-114] to 24 IU/L [18-33], $p < 0.001$, and 58 IU/L [40-100] to 18 IU/L [13-26], $p < 0.001$, respectively. Transaminase values normalized (**Figure S1**) and remained normal throughout the follow-up in all eradicated patients but nine, whose **had persistently elevated enzymes** transaminases ~~persisted slightly elevated~~ (less than twice upper limit of normal). Six of these latter patients underwent a liver biopsy which showed minimal histological changes without evidence of rejection. After 1 week of therapy, the median decrease in HCV RNA was ~~3.87- \log_{10} IU/mL in F3 and 3.55 \log_{10} IU/mL in F4 group ($p=0.002$) (Figures S2 and S3).~~ The overall SVR24 rate was 81.0% (102/126 patients, 95% confidence interval 73.2-86.9) by intention to treat (ITT) analysis (**Figure 1**). **The** SVR24 rate was significantly higher in F3 ~~patients~~ compared with F4 **patients** ones (30/30, 100% vs 72/96, 75%, $p=0.001$); ~~and in~~ patients tolerating $\geq 80\%$ of the full weight-based ribavirin dose ($n=104$) compared with those tolerating $< 80\%$ of the dose ($n=22$) (85.6% vs 59.0%, $p=0.01$) **and in patients with preserved liver function (MELD ≤ 11 and Child $\leq A6$, according to ROC curves) (Figure S2).** **Two cirrhotic patients who became HCV RNA negative on therapy, died for multiresistant bacteria-related septic shock, two others died of liver failure after the EOT: one, 68 years old, had achieved a sustained virological response at week 4 after EOT, the other, 44 years old, had achieved SVR12 and was on the list for retransplantation.** Twenty patients **experienced a** relapsed **of HCV** (17 at week 4, 2 at week 12 and 1 at week 24 of follow-up; the latter cleared HCV RNA at week 4 on therapy and normalized transaminases at week 1). All relapsers were cirrhotic (9 patients Child A, 10 Child B and 1 Child C). They had a median pre-treatment MELD of 13 and had received sofosbuvir and ribavirin; a **the** majority of them were *IL28B* non-C/C genotype (80%) and experienced to previous antiviral therapy (65%) (**Tables S1 and S2**). **Basal median LS was 28.0 kPa in**

1
2
3 the relapsers and 20.4 kPa in the cirrhotics who achieved viral eradication ($p=0.01$). APRI
4
5 and FIB-4 were significantly higher in relapsers compared with responders at baseline
6
7 (3.27 vs 1.92 and 8.45 vs 5.95, respectively; $p < 0.01$ for both) (Table 2).
8

9
10 From baseline to EOT, their median Child improved in relapsers from B7 to A6 ($p=0.014$),
11
12 while the median MELD remained 13. Two patients died at 138 and 160 days after relapse
13
14 due to progressive end-stage liver disease. Seventeen patients started a second treatment
15
16 course, at a median of 17 weeks (range 5-43 weeks) from the relapse. No significant
17
18 variation in liver function tests was observed between relapse and retreatment. (Table S2).
19
20 One patient refused retreatment.
21

22
23 Two cirrhotic patients who were HCV RNA negative on therapy, died for multiresistant
24
25 bacteria-related septic shock; 2 others died of liver failure after the EOT: one, 68 years old,
26
27 had achieved a sustained virological response at week 4 after EOT, and one, 44 years old,
28
29 had achieved SVR12 and was on the list for retransplantation.
30

31
32 In the cirrhotic patients, significant predictors of SVR24 at univariate analysis (Figure 2)
33
34 were MELD ≤ 11 , Child $\leq A6$ and LS ≤ 26 kPa. The cut-offs were chosen according to ROC
35
36 curves: area under the curve (AUC) for MELD 0.723, $p=0.001$; Child 0.759, $p < 0.001$ and
37
38 LS 0.751, $p=0.002$ (Figures S4 and S5).
39

40
41 Basal median LS was 28.0 kPa in the relapsers and 20.4 kPa in the cirrhotics who
42
43 achieved viral eradication ($p=0.01$). APRI and FIB-4 at baseline were significantly higher in
44
45 relapsers compared with responders (3.27 vs 1.92 and 8.45 vs 5.95, respectively; $p < 0.01$
46
47 for both) (Table S3).
48

49
50 Overall, in the cirrhotic group, between baseline and the last available follow-up, 20
51
52 patients (20.8%) showed had a stable MELD from baseline to the last available follow-up
53
54 visit and 43 (44.8%) improved the score of at least 1 point; 46 patients (47.9%) showed had
55
56 a stable Child and 35 (36.5%) improved the score of at least 1 point.
57
58
59
60

Clinical outcomes in patients who achieved viral eradication

In the F3 patients, liver and kidney function remained normal (**Table S34**). APRI and FIB-4 were significantly lower at week 24 after EOT, compared with pre-treatment median values (1.07 to 0.41, $p < 0.001$, and 3.26 to 2.08, $p < 0.001$, respectively); these indexes remained stable in the 28 patients who reached 48 weeks of follow-up (**Figure 13, Panels A and C**). LS (available in 27 patients) improved from 11.0 kPa [10.1-12.0] to 7.7 kPa [6.6-10.2], $p < 0.001$, at week 24 and remained stable at week 48 (7.8 kPa [7.0-10.6], $p = 0.65$ vs week 24) (**Figure 24, Panel A**). In 18 patients (66.7%) LS decreased below the 9.5 kPa cut-off for F3 at week 48.

At week 24 after EOT, the 72 F4 patients who **had** achieved viral eradication **eradicated HCV**, **showed** **exhibited** a significant improvement in platelets count, bilirubin and albumin levels, degree of ascites and Child score at pair wise comparison with baseline values [the rate of Child A was 77.8% (56/72) at baseline and 88.9% (64/72) at week 24 of follow-up]; kidney function and MELD score did not vary. Seventy-one of the 72 responders reached 48 weeks of follow-up and showed a further significant increase in platelets count; albumin, ascites, and Child score [93% (66/71) Child A] remained stable (**Table 32**).

Both APRI and FIB-4 decreased significantly at week 24 after EOT compared with baseline values (1.92 to 0.55, $p < 0.001$, and 5.95 to 3.15, $p < 0.001$, respectively), and further decreased at week 48, compared with 24 week values (APRI 0.51, $p < 0.001$; FIB-4 3.12, $p < 0.001$) (**Figure 13, Panels B and D**). Fifty-one of the 72 patients underwent transient elastography at baseline and at SVR24; the median LS improved from 20.4 kPa [16.0-33.8] to 17.5 kPa [11.1-25.7], $p < 0.001$ (**Figure 24, Panel B**). Fifty patients underwent transient elastography also at week 48 after EOT; the median LS (14.0 kPa [10.0-21.3]) significantly decreased compared with week 24 ($p = 0.001$); in 21 of them (42%) the LS fell below the 12.5 kPa cut-off.

1
2
3 As evaluated by transient elastography in F3-F4 patients pooled together, **in** 39 (50.6%)
4 of the 77 (50.6%) **F3-F4** responders **pooled together**, the fibrosis stage had regressed in
5 transient elastography by at least one Metavir stage at week 48 after EOT.
6
7

8
9 No patients developed hepatocellular carcinoma in the period of observation.
10

11 Thirteen out of the 20 cirrhotic responders with large oesophageal varices at baseline,
12 underwent a second 48 week follow-up endoscopy; **no change in the size of varices was**
13 **observed**. ~~which showed no changes.~~
14
15
16
17
18
19

20 21 Safety

22 AE are summarized in **Table S45**.
23

24 During therapy, seven cirrhotic patients were hospitalised: two patients for grade 3
25 encephalopathy, two for severe variceal bleeding and three for sepsis in decompensated
26 liver disease. Six cirrhotic patients died of complications of end-stage liver disease,
27 unrelated to antiviral therapy.
28
29

30 Three patients discontinued ribavirin for less than 1 week due to diffuse macular skin rash
31 and no one discontinued therapy permanently due to AE.
32
33

34 Because of anemia and/or compromised renal function, 34.1% (43/126) of the patients
35 were treated with a non weight-based escalating dose of ribavirin, starting from 400 mg
36 daily and 11.1% (14/126) required dosage reduction; however, 82.5% (104/126) received
37 at least 80% of the weight-based dosage. Median daily ribavirin dose was 1000 mg from
38 baseline to EOT and median haemoglobin level declined from 12.8 g/dL at baseline to 10.9
39 g/dL at week 4 and remained stable around 10.8 g/dL from week 8 to week 24 (**Figure**
40 **S36**). In 60 patients (47.6%) we measured at least one haemoglobin level of less than 10
41 g/dL and in 12 (9.5%) of less than 8.5 g/dL; 45 patients (35.7%) received epoetin and 14
42 (11.1%) required blood transfusion.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Minimal dose adjustments in the calcineurin inhibitors were required throughout the
4
5 treatment in 64% of the patients (27% increased, 12% decreased and 25% both
6
7 decreased and increased the dose) to maintain stable trough levels. No biopsy-proven
8
9 acute rejection occurred.
10

11 12 13 **DISCUSSION**

14
15
16 The advent of highly effective and well tolerated DAAs against the HCV is revolutionizing
17
18 the outcome of LT for hepatitis C. In this setting, early treatment after surgery is expected
19
20 to be the most cost-effective strategy for patients who are still viremic at LT [10, 14],
21
22 nevertheless DAAs are providing rescue also to residual cohorts of re-infected transplant
23
24 recipients who developed advanced HCV disease [7, 8, 15]. When sofosbuvir became
25
26 available in Italy in June 2014, these patients received priority access to the new therapy
27
28 through a compassionate use program. A majority were treated with sofosbuvir and
29
30 ribavirin; a small minority received the combination of sofosbuvir, ribavirin and simeprevir,
31
32 which became available almost at the end of the enrollment period.
33
34

35
36 After a median follow-up of 461 days from EOT, 102 (81%) of our 126 patients are free of
37
38 HCV and clinically stable. SVR was obtained also in a high proportion (95%) of the 21
39
40 patients with genotype 3, though this genotype is the most difficult to treat in the ordinary
41
42 clinical context. All treatment failures, excluding deceased patients, were due to virologic
43
44 relapses and all relapses, except one, occurred within the first 12 weeks after EOT.
45
46

47
48 Response to therapy was independent from gender, HCV genotype, basal viremia, rapid-
49
50 virologic response, HLA-DRB1*11 phenotype and *IL28B* polymorphisms, while it was
51
52 influenced by the stage of fibrosis and by intolerance to ribavirin: 75% of the patients with
53
54 cirrhosis achieved an SVR compared to 100% of those with F3 fibrosis and among the 22
55
56 patients who tolerated less than 80% of the optimal ribavirin dosage, only 59% obtained an
57
58 SVR. As expected, anemia was the main complication of ribavirin.
59
60

1
2
3 Considering the higher proportion of patients with cirrhosis in this study, our results appear
4 better than the 70% rate of SVR12 reported by Charlton [16] in a smaller series of 40
5 patients recruited in a multicenter study, of whom only 40% were cirrhotics; possibly the
6 management of the patients in a single center adopting a common approach may lead to
7 more uniform results. Though our results are distinctly better than the 43% response
8 reported by Forns et al [7], their series included a mixed population of compensated and
9 decompensated cirrhotics in which a substantial number of patients had a higher MELD
10 score and more severe disease than our patients.
11

12 There were in our study six deaths due to complications of the liver disease, two occurring
13 in patients who had cleared the HCV. The deceased patients had a higher MELD score,
14 ranging from 14 to 19, in confirmation that a deteriorated liver function may prevent clinical
15 improvement despite the antiviral efficacy of treatment [17]; vice versa a preserved liver
16 function expressed by a Child Pugh score ≤ 6 and a MELD ≤ 11 was associated with SVR.
17 Unfortunately, the threshold that may predict the lack of a clinical advantage despite the
18 efficacy of therapy is difficult to establish [17].
19

20 In our 72 cirrhotic responders, SVR24 was associated with the normalization of
21 aminotransferases in almost all patients, accompanied by a decrease of bilirubin and an
22 increase of albumin levels; renal function deteriorated in none and ascites disappeared in
23 three quarters of cases. The platelet count increased throughout therapy, presumably
24 related to the administration of epoetin and to an increased production of endogenous
25 erythropoietin, secondary to ribavirin-induced anemia [18]. The platelet number diminished
26 to baseline values at week 12 post-therapy, but then climbed back significantly at week 24
27 and further increased at week 48; this trend and the regression of ascites may **might** be
28 expression of an initial reduction in portal hypertension.
29

30 The APRI and FIB-4 indexes significantly improved throughout the follow-up; as
31 aminotransferases and platelets are major components for their calculation, the
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 improvement can be explained by the normalization of the enzymes and by the increase in
4
5 the platelet count.

6
7 Transient elastography LS values were significantly reduced at the 6th month of follow-up;
8
9 this early improvement presumably resulted for a large extent by ~~the~~ **from** the decrease of
10
11 inflammation and edema which may artificially alter elastography. Interestingly, however,
12
13 LS values showed a further significant decrease during the subsequent 6 month follow-up
14
15 in patients with cirrhosis. Considering that artefacts due to liver inflammation could no
16
17 longer be implicated, it is plausible that the observed continuing decrease of LS after the
18
19 SVR24 corresponded to a genuine progressive reduction of fibrosis. In agreement with
20
21 previous findings of fibrosis reversion in non-transplant patients with HCV cirrhosis who
22
23 responded to interferon-therapy [19-21], our data would suggest that regression of fibrosis
24
25 starts early and may become already measureable by transient elastography in the first
26
27 year after therapy.
28
29
30

31
32 In conclusion, our experience in a large single center LT cohort of advanced recurrent HCV
33
34 disease, confirms the major therapeutic impact of sofosbuvir with ribavirin, extending also
35
36 to difficult-to-treat genotype 3 patients.
37

38
39 We acknowledge that a new wave of more efficacious DAA combinations is now available
40
41 to treat hepatitis C [8, 15, 22]. Nevertheless, this study provides a paradigm of the
42
43 excellent clinical outcome **and of the potential for disease reversibility after** ~~that can be~~
44
45 ~~expected with~~ successful DAA therapy in the transplant setting.
46
47
48

49 **ACKNOWLEDGEMENTS**

50
51 No ~~specific~~ funding was obtained for this study.
52
53
54
55
56
57
58
59
60

REFERENCES

- [1] Adam R, Karam V, Delvart V. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol* 2012;57:675-688.
- [2] Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. *Gastroenterology* 2002;122:889–896.
- [3] Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. *Gastroenterology* 2012;142:1373-1383.
- [4] Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. *J Hepatol* 2008;49:274-287.
- [5] Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. *J Hepatol* 2014;60:78-86.
- [6] EASL recommendations on treatment of hepatitis C 2015. *J Hepatol* 2015;63:199-236.
- [7] Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. *Hepatology* 2015;61:1485-1494.
- [8] Brown RS Jr, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR Jr, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCV-TARGET. *Liver Transpl* 2016;22:24-33.
- [9] Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol* 2008;48:835-847.
- [10] Romagnoli R, Martini S, Tandoi F, Dell Olio D, Magistroni P, Bertinetto FE, et al. Early reduced liver graft survival in hepatitis C recipients identified by two combined

1
2
3 genetic markers. *Transpl Int* 2016; doi: 10.1111/tri.12795.

4
5 [11] Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al.
6
7 FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with
8
9 liver biopsy and fibrotest. *Hepatology* 2007;46:32-36.

10
11 [12] Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS,
12
13 et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in
14
15 patients with chronic hepatitis C. *Hepatology* 2003;38:518-526.

16
17 [13] Salizzoni M, Franchello A, Smedile A, David E, Barbui A, Torrani M, et al. Marginal
18
19 grafts: finding the correct treatment for fatty livers. *Transpl Int* 2003;16:486-493.

20
21 [14] Russo FP, Zanetto A, Burra P. Timing for treatment of HCV recurrence after liver
22
23 transplantation: the earlier the better. *Transpl Int* 2015;2016;29:694-697.
24
25
26
27 doi:10.1111/tri.12739.

28
29 [15] Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, et al. Ledipasvir
30
31 and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver
32
33 disease. *Gastroenterology* 2015;149:649-659.

34
35 [16] Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofosbuvir
36
37 and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver
38
39 transplantation. *Gastroenterology* 2015;148:108-117.

40
41 [17] Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, et al.
42
43 Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity
44
45 but no clinical benefit if treatment is given late. *Dig Liver Dis* 2014;46:923-927.

46
47 [18] Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, et al. Anemia and
48
49 thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. *J*
50
51
52
53
54
55
56
57
58
59
60
Gastroenterol 2012;47:1228-1237.

[19] Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact
of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic

1
2
3 hepatitis C. *Gastroenterology* 2002;122:1303-1313.

4
5 [20] EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver
6
7 disease severity and prognosis. European Association for the Study of the Liver. *J Hepatol*
8
9 2015;63:237-264.

10
11 [21] D'Ambrosio R, Aghemo A, Fraquelli M, Rumi MG, Donato MF, Paradis V, et al. The
12
13 diagnostic accuracy of Fibroscan[®] for cirrhosis is influenced by liver morphometry in HCV
14
15 patients with a sustained virological response. *J Hepatol* 2013;59:251-256.

16
17 [22] Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al. HCV
18
19 Research UK. Cohort study of the impacts of direct acting antiviral therapy in patients with
20
21 chronic hepatitis C and decompensated cirrhosis. *J Hepatol* 2016;64:1224-1231.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic and baseline characteristics of recipients and donors

Recipient features (N=126)	
Age (years)	60 [54-66]
Male	99 (78.6%)
Body Mass Index (Kg/m²)	24.6 [22.5–26.9]
25-OH vitamin D^x (<20 ng/mL)	71 (59.2%)
HLA-DRB1*11 positive phenotype	34 (27.0%)
<i>IL28B</i> genotype	
rs 12979860 C/C	32 (25.4%)
rs 8099917 T/T	59 (46.8%)
Previous antiviral treatment	83 (65.9%)
Antiviral treatment after LT	57 (45.2%)
Immunosuppressive drug	
CsA – Tac – MMF – other	50 (39.7%) – 56 (44.4%) – 56 (44.4%) – 5 (4.0%)
Time since LT (years)	4.3 [2.3–7.2]
HCV genotype	
1a - 1b - 1 (unspecified)	17 (13.5%) – 70 (55.6%) – 6 (4.8%)
2 - 3 – 4	6 (4.8%) – 21 (16.7%) – 6 (4.8%)
Baseline HCV RNA (log₁₀ IU/mL)	6.40 [6.10–6.66]
≥ 10 ⁶ IU/mL	101 (80.2%)
Corresponding Metavir fibrosis stage	
F3 – F4	30 (23.8%) – 96 (76.2%)
Haemoglobin (g/dL)	12.8 [11.4–14.4]
Platelets count (10⁹/L)	99 [67-140]
Liver enzymes (IU/L)	
Aspartate aminotransferase	60 [40-101]
Alanine aminotransferase	69 [45-116]
γ-Glutamyltransferase	75 [41-152]

Total bilirubin (mg/dL)	1.1 [0.7–1.8]
INR	1.07 [0.98–1.22]
Albumin (g/dL)	3.9 [3.6–4.3]
eGFR* (mL/min)	70 [54-87]
MELD score[§]	10 [8-13]
Child class[§] A – B – C	65 (67.7%) – 27 (28.1%) – 4 (4.2%)
Ascites[§]	38 (39.6%)
Encephalopathy[§]	12 (12.5%)
Presence of varices[§]	26 (27.1%)
Donor features (N=126)	
Age (years)	62 [50–71]
Male	69 (54.8%)
Split liver graft	2 (1.6%)
Graft quality[^] suboptimal[#]	57 (47.5%)
Cold ischemia time (minutes)	486 [424–545]
Donor/Recipient match	
D-MELD	982 [666–1303]

Numerical variables are expressed as median [Q1-Q3]. Categorical variables are expressed as numbers (prevalence, %).

[^]6 missing data

^{*}Chronic Kidney Disease Epidemiology Collaboration equation

[§]In 96 cirrhotic patients

[#]According to Salizzoni et al, Transpl Int 2003

Abbreviations: CsA, cyclosporine; D-MELD, donor age x recipient MELD; eGFR, estimated glomerular filtration rate; F, fibrosis; HCV, hepatitis C virus; HLA, human leukocyte antigen; IL28B, Interleukin 28B; LT, liver transplantation; MELD, Model for End-stage Liver Disease; MMF, mycophenolate mofetil; Tac, tacrolimus.

Table 2. Liver function tests and non-invasive markers of fibrosis at baseline and at the end of therapy in responder versus relapser cirrhotic patients

BASELINE	Responders (n=72)	Relapsers (n=20)	p[#]
APRI	1.92 [1.00-3.27]	3.27 [1.72-5.51]	0.007
FIB-4	5.95 [3.60-11.10]	8.45 [7.17-16.08]	0.009
Liver stiffness* (kPa)	20.4 [16.0-33.8]	28.0 [21.6-44.4]	0.01
Child score	5 [5-6]	7 [6-8]	0.002
MELD score	10 [8-12]	13 [9-16]	0.02
EOT	Responders (n=72)	Relapsers (n=20)	p[#]
APRI	0.46 [0.29-0.76]	0.83 [0.57-1.22]	0.02
FIB-4	3.25 [1.90-4.30]	4.80 [3.71-7.42]	0.01
Liver stiffness* (kPa)	17.5 [11.1-25.7]	23.4 [18.3-39.0]	0.09
Child score	5 [5-6]	6 [5-7]	0.19
MELD score	11 [9-14]	13 [11-17]	0.05

Numerical variables are expressed as median [Q1-Q3]

*Liver stiffness was available at baseline in 51 responders and 17 relapsers; at EOT in 51 responders and 13 relapsers

[#]p-values calculated according to Wilcoxon test for paired data

Abbreviations: APRI, AST to platelet ratio index; EOT, end of therapy; kPa, kilopascal; MELD, Model for End-stage Liver Disease.

Table 32. Clinical and biochemical variations in cirrhotic long-term responder cirrhotic patients who achieved viral eradication

	Baseline (N=72)	EOT (N=72)	SVR12 (N=72)	SVR24 (N=72)	SVR48 (N=71°)	p [^]	p [§]
AST (IU/L)	69 [47-97]	23 [20-28]	27 [22-35]	24 [18-32]	21 [18-28]	<0.001	0.13
ALT (IU/L)	59 [41-90]	15 [11-23]	18 [14-27]	16 [12-25]	17 [12-27]	<0.001	0.02
Bilirubin (mg/dL)	1.1 [0.8-1.5]	1.4 [1.1-2.2]	0.9 [0.6-1.2]	0.8 [0.6-1.2]	0.9 [0.6-1.1]	<0.001	0.74
INR	1.06 [0.99-1.20]	1.11 [1.07-1.24]	1.09 [1.02-1.24]	1.08 [1.02-1.22]	1.11 [1.07-1.23]	0.03	0.007
Albumin (g/dL)	3.9 [3.6-4.3]	4.1 [3.8-4.4]	4.1 [3.7-4.3]	4.2 [3.8-4.4]	4.3 [4.0-4.5]	0.02	0.31
Creatinine (mg/dL)	1.1 [0.9-1.3]	1.1 [0.9-1.3]	1.0 [0.9-1.3]	1.1 [1.0-1.3]	1.1 [0.9-1.3]	0.36	0.12
eGFR* (mL/min)	68 [52-84]	64 [52-80]	67 [53-83]	63 [52-78]	62 [52-82]	0.26	0.25
Platelets (10⁹/L)	99 [65-134]	131 [86-185]	99 [64-133]	108 [72-142]	112 [68-144]	0.002	0.01
Ascites	22 (30.6%)	12 (16.7%)	8 (11.1%)	7 (9.7%)	7 (9.9%)	0.003	>0.99
Encephalopathy	5 (6.9%)	4 (5.6%)	3 (4.2%)	3 (4.2%)	2 (2.8%)	0.72	>0.99
MELD score	10 [8-12]	11 [9-14]	9 [8-11]	9 [8-11]	10 [8-11]	0.34	0.92
Child score	5 [5-6]	5 [5-6]	5 [5-6]	5 [5-5]	5 [5-5]	<0.001	0.68

Numerical variables are expressed as median [Q1-Q3]. Categorical variables are expressed as numbers (prevalence,%).

p-values calculated according to Wilcoxon test for paired data for numerical variables and according to Fisher's exact test for categorical variables.

°71 out of 72 cured patients reached 48 weeks of follow-up after therapy

*Chronic Kidney Disease Epidemiology Collaboration equation

^Baseline versus SVR24

§SVR24 versus SVR48

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; EOT, end of therapy; MELD, Model for End-stage Liver Disease; SVR12, sustained virological response at week 12 after end of therapy; SVR24, sustained virological response at week 24 after end of therapy; SVR48, sustained virological response at week 48 after end of therapy.

FIGURE LEGENDS

Figure 1. Sustained virological response rates by intention to treat analysis according to fibrosis stage. SVR, sustained virological response; F, fibrosis according to Metavir; SVR12, sustained virological response at week 12 after therapy; SVR24, sustained virological response at week 24 after therapy.

Figure 2. Sustained virological response rates at week 24 after therapy in the 96 cirrhotic patients. SVR24, sustained virological response at week 24 after therapy; CI, confidence interval; *IL28B*, *Interleukin 28B*; HLA, human leukocyte antigen; TW4, week 4 on therapy; MELD, Model for End-stage Liver Disease; APRI, AST to platelet ratio index; kPa, kilopascal.

Figure 13. Variations of from baseline to weeks 24 and 48 after therapy in APRI (Panels A and B) and FIB-4 (Panels C and D) from baseline to weeks 24 and 48 after therapy, in F3 and F4 long-term responders. patients who achieved viral eradication. APRI, AST to platelet ratio index; F, fibrosis according to Metavir; SVR24, sustained virological response at week 24 after therapy; SVR48, sustained virological response at week 48 after therapy.

Figure 24. Variations in of liver stiffness from baseline to weeks 24 and 48 after therapy in F3 (Panel A) and F4 patients (Panel B) who achieved viral eradication long-term responders. F, fibrosis according to Metavir; kPa, kilopascal; SVR24, sustained virological response at week 24 after therapy; SVR48, sustained virological response at week 48 after therapy.




Figure 1. Variations of APRI (Panels A and B) and FIB-4 (Panels C and D) from baseline to weeks 24 and 48 after therapy, in F3 and F4 long-term responders. APRI, AST to platelet ratio index; F, fibrosis according to Metavir; SVR24, sustained virological response at week 24 after therapy; SVR48, sustained virological response at week 48 after therapy.

194x236mm (72 x 72 DPI)




Figure 2. Variations of liver stiffness from baseline to weeks 24 and 48 after therapy in F3 (Panel A) and F4 (Panel B) long-term responders. F, fibrosis according to Metavir; kPa, kilopascal; SVR24, sustained virological response at week 24 after therapy; SVR48, sustained virological response at week 48 after therapy.

260x142mm (72 x 72 DPI)

Review